Last updated: February 21, 2024
Sponsor: Greenyn Biotechnology Co., Ltd.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Diabetic Kidney Disease
Diabetic Retinopathy
Diabetic Vitreous Hemorrhage
Treatment
Pumpkin seed extract (High dose)
Pumpkin seed extract (Low dose)
Placebo
Clinical Study ID
NCT05738655
A-111-110
Ages 20-75 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Fasting blood sugar levels from 100 to 125 mg/dL
- Glycated hemoglobin levels from 5.7 to 6.4%
- 2-hour OGTT levels from 140 to 199 mg/dL
Exclusion
Exclusion Criteria:
- Pregnant women or preparing for pregnancy.
- Lactating women.
- Women gave birth 6 months before the study.
- Poor kindy funciton
- Severe cardiovascular or other chronic diseases
- Patients with type I or II diabetes
- Poor compliance
- Alcohol abuser
- Using anti-diabetic or weight managent supplements
- Blood transfusion three months before the study
- Pumpkin seed allergy
Study Design
Total Participants: 60
Treatment Group(s): 3
Primary Treatment: Pumpkin seed extract (High dose)
Phase:
Study Start date:
March 01, 2023
Estimated Completion Date:
October 31, 2024
Connect with a study center
WanFang Hospital
Taipei, 116
TaiwanActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.